| Methods |
Crossover design; each phase 7 days. All patients completed the study correctly. Said to be double blind, with placebos used, but no other details. Not double blind for dose comparison. Concurrent asthma medication ‐ sodium cromoglycate. |
| Participants |
Inclusion criteria: patients had asthma ‐ diagnosis according to ACCP‐ATS criteria; stable asthma medication; recent nocturnal asthma. Exclusions: CV, ocular & genito‐urinary diseases; history of intolerance to theophylline or anti‐muscarinic agents. Patient details: 12 participants; age 18‐60; mild asthma; no information on concurrent COPD or atopy. |
| Interventions |
2 interventions: oxitropium bromide 400/600µg, placebo by MDI; all interventions t.i.d. (unclear when). |
| Outcomes |
% change daily PEF(morning/
max PEF; not analysed), symptom scores (night or morning ‐ no numbers); % predicted FEV1 at end of period (not analysed). |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
Information not available (Cochrane Grade B) |
